Современные подходы к ведению детей с внебольничной пневмонией

Экспертами Союза педиатров России разработаны актуальные клинические рекомендации по оказанию медицинской помощи детям с внебольничными пневмониями, которые были одобрены Научно-практическим советом Минздрава России в январе 2022 г. Особое внимание уделено этиологической структуре, современной классификации, диагностическим исследованиям и основным подходам к антибактериальной терапии внебольничной пневмонии у детей, основанным на принципах доказательной медицины. 

1. Геппе Н.А., Розинова Н.Н., Волков И.К., Мизерницкий Ю.Л. Рабочая классификация основных клинических форм бронхолегочных заболеваний у детей // Трудный пациент. — 2009. — Т. 7. — № 1-2. — С. 35–39.

2. Bradley JS, Byington CL, Shah SS, et al. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):617–630. doi: https://doi.org/10.1093/cid/cir625

3. Pocket book of hospital care for children: Guidelines for the management of common childhood illnesses. 2nd ed. Geneva: World Health Organization; 2013.

4. Внебольничная пневмония у детей: клинические рекомендации / Российское респираторное общество; Межрегиональное педиатрическое респираторное общество; Федерация педиатров стран СНГ; Московское общество детских врачей. — М.: Оригинал-макет; 2015. — 64 с.

5. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113(4):701–707. doi: https://doi.org/10.1542/peds.113.4.701

6. Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835–845. doi: https://doi.org/10.1056/NEJMoa1405870

7. Yun KW, Wallihan R, Juergensen A, et al. Community-Acquired Pneumonia in Children: Myths and Facts. Am J Perinatol. 2019;36(S02):S54–S57. doi: https://doi.org/10.1055/s-0039-1691801

8. Kaz SE, Wiliams D. Pediatric community-acquired pneumonia in the United States: changing epidemiology, diagnostic and therapeutic challenges, and areas for future research. Infect Dis Clin North Am. 2018;32(1):47–63. doi: https://doi.org/10.1016/j.idc.2017.11.002

9. Gareca Perales J, Soleto Ortiz L, Loayza Mafayle R, et al. Diagnosis of Community-acquired Pneumonia in Hospitalized Children. A Multicenter Experience in Bolivia. Pediatr Infect Dis J. 2021;40(1):32–38. doi: https://doi.org/10.1097/INF.0000000000002909

10. Rhedin S, Lindstrand A, Hjelmgren A, et al. Respiratory viruses associated with community-acquired pneumonia in children. Matched Case-Control study. Thorax. 2015;70(9):847–853. doi: https://doi.org/10.1136/thoraxjnl-2015-206933

11. Таточенко В.К., Федоров А.М., Краснов М.В. и др. Острые пневмонии у детей / под ред. В.К. Таточенко. — Чебоксары: Издательство Чувашского университета; 1994. — 323 с.

12. Pritt BS, Aubry MC. Histopathology of viral infections of the lung. Semin Diagn Pathol. 2017;34(6):510–517. doi: https://doi.org/10.1053/j.semdp.2017.06.005

13. Самсонова М.В., Черняев А.Л., Михалева Л.М. и др. Патологическая анатомия легких при СOVID-19. Доступно по: https://patologoanatom.belzdrav.ru/upload/0_patologoanatom/covid-19/0605/mv_samsonova_covid-19_.pdf. Ссылка активна на 14.02.2022.

14. Stoll BJ, Hansen NI, Higgins RD, et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002–2003. Pediatr Infect Dis J. 2005;24(7):635–639. doi: https://doi.org/10.1097/01.inf.0000168749.82105.64

15. Mishaan AM, Mason EO Jr, Martinez-Aguilar G, et al. Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas. Pediatr Infect Dis J. 2005;24(3):201–206. doi: https://doi.org/10.1097/01.inf.0000151107.29132.70

16. Proportions of child death by cause: Global Health Observatory. Geneva: World Health Organization; 2014.

17. Kucova P, Kantor L, Fiserova K, et al. Bacterial Pathogens and Evaluation of a Cut-Off for Defining Early and Late Neonatal Infection. Antibiotics (Basel). 2021;10(3):278. doi: https://doi.org/10.3390/antibiotics10030278

18. Nascimento-Carvalho CM, Ribeiro CT, Cardoso MR, et al. The role of respiratory viral infections among children hospitalized for community-acquired pneumonia in a developing country. Pediatr Infect Dis J. 2008;27(10):939–941. doi: https://doi.org/10.1097/INF.0b013e3181723751

19. American Academy of Pediatrics Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedules — United States, 2009. Pediatrics. 2009;123(1):189– 190. doi: https://doi.org/10.1542/peds.2008-3306

20. Tsolia MN, Psarras S, Bossios A, et al. Etiology of communityacquired pneumonia in hospitalized school-age children: evidence for high prevalence of viral infections. Clin Infect Dis. 2004;39(5):681–686. doi: https://doi.org/10.1086/422996

21. Tajima T, Nakayama E, Kondo Y, et al. Etiology and clinical study of community-acquired pneumonia in 157 hospitalized children. J Infect Chemother. 2006;12(6):372–379. doi: https://doi.org/10.1007/s10156-006-0476-5

22. Marangu D, Zar HJ. Childhood pneumonia in low-and-middleincome countries: An update. Paediatr Respir Rev. 2019;32:3–9. doi: https://doi.org/10.1016/j.prrv.2019.06.001

23. Esposito S, Patria MF, Tagliabue C, et al. CAP in chil-dren. In: European Respiratory Monograph 63: Community-Acquired Pneumonia. Chalmers J, Pletz M, Aliberti S, eds. 2014. pp. 130– 139.

24. Кузьменков А.Ю., Трушин И.В., Авраменко А.А. и др. AMRmap: Интернет-платформа мониторинга антибиотикорезистентности // Клиническая микробиология и антимикробная химиотерапия. — 2017. — Т. 19. — № 2. — С. 84–90.

25. Баранов А.А., Намазова Л.С., Таточенко В.К. Пневмококковая инфекция и связанные с ней заболевания — серьезная проблема современного здравоохранения // Педиатрическая фармакология. — 2008. — Т. 5. — № 1. — С. 7–12.

26. Козлов Р.С., Синопальников А.И., Зайцева О.В. и др. Ингибиторозащищенный амоксициллин с повышенным содержанием амоксициллина и соотношением действующих компонентов 14:1: место в лечении внебольничных инфекций дыхательных путей и ЛОР-органов у детей. Резолюция Экспертного совета // Клинический разбор в общей медицине. — 2021. — № 2. — С. 6–14. — doi: https://doi.org/10.47407/kr2021.2.1.00036.

27. Torumkuney D, Mayanskiy N, Edelstein M, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014–16 in Russia. J Antimicrob Chemother. 2018;73(Suppl_5):v14–v21. doi: https://doi.org/10.1093/jac/dky065

28. Иванова О.В., Эйдельштейн И.А., Ромашов О.И., Козлов Р.С. Оценка влияния мутаций в гене 23S рРНК Mycoplasma pneumoniae, обуславливающих устойчивость к макролидам, на тяжесть течения внебольничной пневмонии у лиц молодого возраста, находившихся на лечении в Смоленском военном госпитале // Клиническая микробиология и антимикробная химиотерапия. — 2020. — Т. 22. — № 4. — С. 306–312. — doi: https://doi.org/10.36488/cmac.2020.4.306-312

29. Анализ распространенности мутаций резистентности к макролидам и фторхинолонам у Mycoplasma genitalium и Mycoplasma pneumoniae // AMRcloud. — 08 апреля 2021. [Prevalence of macrolide and fluoroquinolone resistancemediating mutations in Mycoplasma genitalium and Mycoplasma pneumoniae. In: AMRcloud. April 08, 2021. (In Russ).] Доступно по: https://amrcloud.net/ru/project/demares. Ссылка активна на 14.02.2022.

30. Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H. Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Organ. 2004;82(12):895–903.

31. Заболеваемость населения России в 2000–2009 гг. Статистические материалы МЗСР РФ.

32. Козлов Р.С., Кречикова О.И., Муравьев А.А. и др. Результаты исследования распространенности в России внебольничной пневмонии и острого среднего отита у детей в возрасте до 5 лет (PAPIRUS). Роль S. pneumoniae и H. influenzae в этиологии данных заболеваний // Клиническая микробиология и антимикробная химиотерапия. — 2013. — Т. 15. — № 4. — С. 246– 260.

33. Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66 Suppl 2;ii1–23. doi: https://doi.org/10.1136/thoraxjnl-2011-200598

34. Levels and trends in child mortality: Report 2014. United Nations Inter Agency Group for Child Mortality Estimation. UNICEF, WHO, The World Bank, United Nations Population Divisoin. New York; 2014.

35. Revised WHO classification and treatment of childhood pneumonia at health facilities: evidence summaries. Geneva: World Health Organization; 2014.

36. Wingerter SL, Bachur RG, Monuteaux MC, Neuman MI. Application of the World Health Organization criteria to predict radiographic pneumonia in a US-based pediatric emergency department. Pediatr Infect Dis J. 2012;31(6):561–564. doi: https://doi.org/10.1097/INF.0b013e31824da716

37. Таточенко В.К. Болезни органов дыхания у детей. — 7-е изд. — М.: Боргес; 2019. — 300 с.

38. Rambaud-Althaus C, Althaus F, Genton B, D’Acremont V. Clinical features for diagnosis of pneumonia in children younger than 5 years: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(4):439–450. doi: https://doi.org/10.1016/S1473-3099(15)70017-4.

39. Ginsburg AS, Lenahan JL, Izadnegahdar R, Ansermino JM. A Systematic Review of Tools to Measure Respiratory Rate in Order to Identify Childhood Pneumonia. Am J Respir Crit Care Med. 2018;197(9):1116–1127. doi: https://doi.org/10.1164/rccm.201711-2233CI

40. Boyd K. Back to the Basics: Community-Acquired Pneumonia in Children. Pediatr Ann. 2017;46(7):e257–e261. doi: https://doi.org/10.3928/19382359-20170616-01

41. Søndergaard MJ, Friis MB, Hansen DS, Jørgensen IM.. Clinical manifestations in infants and children with Mycoplasma pneumoniae infection. PLoS One. 2018;13(4):e0195288. doi: https://doi.org/10.1371/journal.pone.0195288

42. Манеров Ф.К. Диагностика и терапия острой пневмонии у детей при разных вариантах течения: дис. … докт. мед. наук. — Новокузнецк; 1990.

43. Таточенко В.К. Внебольничные пневмонии у детей — проблемы и решения // Российский вестник перинатологии и педиатрии. — 2021. — Т. 66. — № 1. — С. 9–21. — doi: https://doi.org/10.21508/1027-4065-2021-66-1-9-21

44. Mcintosh K. Community-Acquired pneumonia in children. N Engl J Med. 2002; 346(6): 429–437. doi: https://doi.org/10.1056/NEJMra011994

45. Crawford SE, Daum RS. Bacterial pneumonia, lung abscess and empyema. In: Pediatric respiratory medicine. Taussig LM, Landau LI, eds. 2nd ed. Mosby, Inc.; 2008. pp. 501–553. doi: https://doi.org/10.1016/B978-032304048-8.50039-6

46. Бакрадзе М.Д., Куличенко Т.В., Митюшин И.Л. и др. Лихорадящий ребенок / под ред. А.А. Баранова. — М.: ПедиатрЪ; 2017. — 320 с.

47. Goodman D, Crocker ME, Pervaiz F. Challenges in the diagnosis of paediatric pneumonia in intervention field trials: recommendations from a pneumonia field trial working group. Lancet Respir Med. 2019;7(12):1068–1083. doi: https://doi.org/10.1016/S2213-2600(19)30249-8

48. Thomas J, Pociute A, Kevalas R, et al. Blood biomarkers differentiating viral versus bacterial pneumonia aetiology: a literature review. Ital J Pediatr. 2020;46(1):4. doi: https://doi.org/10.1186/s13052-020-0770-3

49. Iroh Tam PY, Bernstein E, Ma X, Ferrieri P. Blood Culture in Evaluation of Pediatric Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Hosp Pediatr. 2015;5(6):324–336. doi: https://doi.org/10.1542/hpeds.2014-0138

50. Bhuiyan MU, Blyth CC, West R. Combination of clinical symptoms and blood biomarkers can improve discrimination between between bacterial or viral community-acquired pneumonia in children. BMC Pulm Med. 2019;19(1):71. doi: https://doi.org/10.1186/s12890-019-0835-5

51. ERS handbook of paediatric respiratory medicine. Eber E, Midulla F, eds. Sheffield: European Respiratory Society; 2013. 719 p.

52. Hosseini SM, Poorolajal J, Karami M, Ameri P. Prevalence of Nasopharyngeal Carriage of Streptococcus pneumonia in Iran: A Meta-Analysis. J Res Health Sci. 2015;15(3):141–146.

53. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7(10):e1000348. doi: https://doi.org/10.1371/journal.pmed.1000348

54. Fernando M de Benedictis FM, Kerem E, Chang AB, et al. Complicated pneumonia in children. Lancet. 2020;396(10253):786– 798. doi: https://doi.org/10.1016/S0140-6736(20)31550-6

55. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19): временные методические рекомендации. Версия 11 от 07.05.2021.

56. Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19) у детей: методические рекомендации. Версия 2 от 03.07.2021.

57. Яцышина С.Б., Спичак Т.В., Ким С.С. и др. Выявление респираторных вирусов и атипичных бактерий у больных пневмонией и здоровых детей за десятилетний период наблюдения // Педиатрия. Журнал им. Г.Н. Сперанского. — 2016. — Т. 95. — № 2. — С. 43–50.

58. Spuesens EB, Fraaij PL, Visser EG, et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med. 2013;10(5):e1001444. doi: https://doi.org/10.1371/journal.pmed.1001444

59. Copete AR, Vera C, Herrera M, et al. Mycoplasma pneumoniae in children with and without community-acquired pneumonia. What do PCR and serology say? Pediatr Infect Dis J. 2020;39(7):e104– e108. doi: https://doi.org/10.1097/INF.0000000000002636.

60. Guiso N, Berbers G, Fry NK, et al. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis. 2011;30(3):307–312. doi: https://doi.org/10.1007/s10096-010-1104-y

61. Dean P, Florin TA. Factors Associated With Pneumonia Severity in Children: A Systematic Review. J Pediatric Infect Dis Soc. 2018;7(4):323–334. doi: https://doi.org/10.1093/jpids/piy046

62. Andronikou S, Lambert E, Halton J, et al. Guidelines for the use of chest radiographs in community-acquired pneumonia in children and adolescents. Pediatr Radiol. 2017;47(11):1405–1411. doi: https://doi.org/10.1007/s00247-017-3944-4

63. Le Roux DM, Zar HJ. Community-acquired pneumonia in children — a changing spectrum of disease. Pediatr Radiol. 2017;47(11):1392–1398. doi: https://doi.org/10.1007/s00247-017-3827-8

64. Levinsky Y, Mimouni FB, Fisher D, Ehrlichman M. Chest radiography of acute paediatric lower respiratory infections: experience versus interobserver variation. Acta Paediatr. 2013;102(7):e310–e314. doi: https://doi.org/10.1111/apa.12249

65. Nascimento-Carvalho CM, Araújo-Neto CA, Ruuskanen O. Association between bacterial infection and radiologically confirmed pneumonia among children. Pediatr Infect Dis J. 2015;34(5):490– 493. doi: https://doi.org/10.1097/INF.0000000000000622

66. Novack V, Avnon LS, Smolyakov A, et al. Disagreement in the interpretation of chest radiographs among specialists and clinical outcomes of patients hospitalized with suspected pneumonia. EurJ Intern Med. 2006;17(1):43–47. doi: https://doi.org/10.1016/j.ejim.2005.07.008

67. Johnson J, Kline JA. Intraobserver and interobserver agreement of the interpretation of pediatric chest radiographs. Emerg Radiol. 2010;17(4):285–290. doi: https://doi.org/10.1007/s10140-009-0854-2

68. Weigl J. Community acquired pneumonia in Germany. In: 21th Annual Meeting of ESPID, Taormina, Sicily, April 9–12, 2003. Abstr. 47. p. 24.

69. Orso D, Ban A, Guglielmo N. Lung ultrasound in diagnosing pneumonia in childhood: a systematic review and meta-analysis. J Ultrasound. 2018;21(3):183–195. doi: https://doi.org/10.1007/s40477-018-0306-5

70. El Fahimi N, Calleja MA, Ratnayake L, Ali I. Audit of a multidisciplinary approach to improve management of communityacquired pneumonia. Eur J Hosp Pharm. 2019;26(4):223–225. doi: https://doi.org/10.1136/ejhpharm-2017-001368

71. Lodha R, Kabra SK, Pandey RM. Antibiotics for communityacquired pneumonia in children. Cochrane Database Syst Rev. 2013;2013(6):CD004874. doi: https://doi.org/10.1186/1471-2431-9-15

72. Infants and Children: Acute Management of Community Acquired Pneumonia: Guideline. NSW Health; 2018. Available online: https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/GL2018_007.pdf. Accessed on February 15, 2023.

73. Амоксициллин Диспертаб®. Регистрационное удостоверение № ЛП-006567. Дата регистрации: 13.11.2022 // Государственный реестр лекарственных средств: официальный сайт. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3235dc2e-7f7b-4d14-875dfe3e1d5a66b1. Ссылка активна на 02.02.2023.

74. Амосин®. Регистрационное удостоверение № ЛС-001736. Дата регистрации: 13.08.2010 // Государственный реестр лекарственных средств: официальный сайт. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=55024c57-ba7a-4584-bfa7-a1a0ab61da4d. Ссылка активна на 02.02.2023.

75. Aurangzeb B., Hameed A. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of communityacquired pneumonia in children. J Coll Physicians Surg Pak. 2003;13(12):704–707.

76. Wubbel L, Muniz L, Ahmed A, et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J. 1999;18(2):98–104. doi: https://doi.org/10.1097/00006454-199902000-00004

77. Schönwald S, Gunjaca M, Kolacny-Babić L, et al. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother. 1990;25 Suppl A:123–126. doi: https://doi.org/10.1093/jac/25.suppl_a.123

78. Ушкалова Е.А. Применение доксициклина у детей и подростков // Фарматека. — 2005. — № 15. — С. 18.

79. Chiappini E, Mazzantini R, Bruzzese E, et al. Rational use of antibiotics for the management of children’s respiratory tract infections in the ambulatory setting: an evidence-based consensus by the Italian Society of Preventive and Social Pediatrics. Paediatr Respir Rev. 2014;15(3):231–236. doi: https://doi.org/10.1016/j.prrv.2013.11.011

80. Mathur S, Fuchs A, Bielicki J, et al. Antibiotic use for communityacquired pneumonia in neonates and children: WHO evidence review. Paediatr Int Child Health. 2018;38(Supp1):S66–S75. doi: https://doi.org/10.1080/20469047.2017.1409455

81. Matsubara K, Morozumi M, Okada T, et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother. 2009;15(6):380–383. doi: https://doi.org/10.1007/s10156-009-0715-7

82. Lee H, Yun KW, Lee HJ, Choi EH. Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Expert Rev Anti Infect Ther. 2018;16(1):23–34. doi: https://doi.org/10.1080/14787210.2018.1414599

83. Leung AKC, Wong AHC, Hon KL. Community-Acquired Pneumonia in Children. Recent Pat Inflamm Allergy Drug Discov. 2018;12(2):136–144. doi: https://doi.org/10.2174/1872213X12666180621163821

84. Цефуроксим. Регистрационное удостоверение № ЛП-000003. Дата регистрации: 02.03.2007 // Государственный реестр лекарственных средств: официальный сайт. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ffcb5e06-1df5-4860-8d95-7bd11e4f869b. Ссылка активна на 02.02.2023.

85. Haider BA, Saeed MA, Bhutta ZA. Short-course versus longcourse antibiotic therapy for non- severe community-acquired pneumonia in children aged 2 months to 59 months. Cochrane Database Syst Rev. 2008;(2):CD005976. doi: https://doi.org/10.1002/14651858.CD005976.pub2

86. Зинфоро®. Регистрационное удостоверение № ЛП-001912. Дата регистрации: 20.11.2012 // Государственный реестр лекарственных средств: официальный сайт. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8035dfec-e622-4f1e-b152-c429567cb058. Ссылка активна на 02.02.2023.

87. Cannavino CR, Nemeth A, Korczowski B, et al. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone. Pediatr Infect Dis J. 2016;35(7):752–759. doi: https://doi.org/10.1097/INF.0000000000001159

88. Pneumonia (community-acquired): antimicrobial prescribing. NICE guideline [NG138]. September 2019. Available online: https://www.nice.org.uk/guidance/ng138. Accessed on February 15, 2023.

89. Nascimento-Carvalho CM. Community-acquired pneumonia among children: the latest evidence for an updated management. J Pediatr (Rio J). 2020;96(Suppl 1):29–38. doi: https://doi.org/10.1016/j.jped.2019.08.003

90. Pernica JM, Harman S, Kam AJ, et al. Short-course antimicrobial therapy for pediatric community-acquired pneumonia. The SAFER randomized clinical trial. JAMA Pediatr. 2021;175(5):475–482. doi: https://doi.org/10.1001/jamapediatrics.2020.6735

91. Same RG, Amoah J, Hsu AJ, et al. The Association of Antibiotic Duration With Successful Treatment of Community-Acquired Pneumonia in Children. J Pediatric Infect Dis Soc. 2021;10(3):267– 273. doi: https://doi.org/10.1093/jpids/piaa055

92. Blaschke AJ, Heyrend C, Byington CL, et al. Molecular analysis imroves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr Infect Dis J. 2011;30(4):289– 294. doi: https://doi.org/10.1097/INF.0b013e3182002d14

93. Bradley JS, Ching DK, Hart CL. Invasive bacterial disease in childhood: efficacy of oral antibiotic therapy following short course parenteral therapy in non-central nervous system infections. Pediatr Infect Dis J. 1987;6(9):821–825.

94. Moreno-Pérez D, Andrés Martín A, Tagarro García A, et al. Community acquired pneumonia in children: Treatment of complicated cases and risk patients. Consensus statement by the Spanish Society of Paediatric Infectious Diseases (SEIP) and the Spanish Society of Paediatric Chest Diseases (SENP). An Pediatr (Barc). 2015;83(3):217.e1–11. doi: https://doi.org/10.1016/j.anpedi.2014.12.002

95. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;4:CD008965. doi: https://doi.org/10.1002/14651858.CD008965.pub3

96. Heneghan CJ, Onakpoya I, Jones MA, et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess. 2016;20(42):1–242. doi: https://doi.org/10.3310/hta20420

97. Реленза. Регистрационное удостоверение № ЛСР000095. Дата регистрации: 31.05.2007 // Государственный реестр лекарственных средств: официальный сайт. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5edcae9f-e8f3-4227-9939-e5aa7fdf1e9b. Ссылка активна на 02.02.2023.

98. Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis. 2011;11:134. doi: https://doi.org/10.1186/1471-2334-11-134

99. Нурофен® для детей. Регистрационное удостоверение № П N014745/01. Дата регистрации: 22.08.2008 // Государственный реестр лекарственных средств: официальный сайт. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=58ea2be8-b33b-4924-9fab97a5825084a6. Ссылка активна на 02.02.2023.

100. Руководство по амбулаторно-клинической педиатрии / под ред. А.А. Баранова. — 2-е изд. — М.: ГЭОТАР-Медиа; 2009.

101. Feld LG, Neuspiel DR, Foster BA, et al. Clinical Practice Guideline: Maintenance Intravenous Fluids in Children. Pediatrics. 2018;142(6):e20183083. doi: https://doi.org/10.1542/peds.2018-3083

102. Duke T, Molyneux EM. Intravenous fluids for seriously ill children: time to reconsider. Lancet. 2003;362(9392):1320–1323. doi: https://doi.org/10.1016/S0140-6736(03)14577-1

103. Barson WJ. Pneumonia in children: Inpatient treatment. In: UpToDate. Available online: https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment?search=pneumonia%20acidosis&source=search_result&selectedTitle=2~150&usage_type=default. Accessed on February 15, 2023.

104. Ambroggio L, Test M, Metlay JP, et al. Adjunct Systemic Corticosteroid Therapy in Children With Community-Acquired Pneumonia in the Outpatient Setting. J Pediatric Infect Dis Soc. 2015;4(1):21–27. doi: https://doi.org/10.1093/jpids/piu017

105. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 1996;15(3):255– 259. doi: https://doi.org/10.1097/00006454-199603000-00015

106. Chang CC, Cheng AC, Chang AB. Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database Syst Rev. 2014;(3):CD006088. doi: https://doi.org/10.1002/14651858. CD006088.pub2

107. Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2017;12(12):CD007720. doi: https://doi.org/10.1002/14651858.CD007720.pub3

108. Tagarro A, Otheo E, Baquero-Artigao F, et al. Dexamethasone for parapneumonic pleural effusion: a randomized, double-blind, clinical trial. J Pediatr. 2017;185:117–23.e6. doi: https://doi.org/10.1016/j.jpeds.2017.02.043

109. Das RR, Singh M, Naik SS. Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia. Cochrane Database Syst Rev. 2018;7(7):CD011597. doi: https://doi.org/10.1002/14651858.CD011597.pub2

110. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013;2013(1):CD000980. doi: https://doi.org/10.1002/14651858.CD000980.pub4

111. Padhani ZA, Moazzam Z, Ashraf A, et al. Vitamin C supplementation for prevention and treatment of pneumonia. Cochrane Database Syst Rev. 2020;4(4):CD013134. doi: https://doi.org/10.1002/14651858.CD013134.pub2

112. Wu T, Ni J, Wei J. Vitamin A for non‐measles pneumonia in children. Cochrane Database Syst Rev. 2005;2005(3):CD003700. doi: https://doi.org/10.1002/14651858.CD003700.pub2

113. Brown N, Roberts C. Vitamin A for acute respiratory infection in developing countries: a meta‐analysis. Acta Paediatr. 2004;93(11):1437–1442. doi: https://doi.org/10.1080/08035250410022143

114. Kumar RM, Kabra SK, Singh M. Efficacy and acceptability of different modes of oxygen administration in children: implications for a community hospital. J Trop Pediatr. 1997;43(1):47–49. doi: https://doi.org/10.1093/tropej/43.1.47

115. Carter E, Waldhausen J, Zhang W, et al. Management of children with empyema: pleural drainage is not always necessary. Pediatr Pulmonol. 2010;45(5):475–480. doi: https://doi.org/10.1002/ppul.21200

116. Малявин А.Г., Епифанов В.А., Глазкова И.И. Реабилитация при заболеваниях органов дыхания. — М.: ГЭОТАР-Медиа; 2010. — 352 с. — (Библиотека врача специалиста).

117. Swingler GH, Michaels D, Hussey GGD. Conjugate vaccines for preventing Haemophilus influenzae type B infections. Cochrane Database Syst Rev. 2003;(4):CD001729. doi: https://doi.org/10.1002/14651858.CD00172

118. The Green Book. Immunization against infections disease. 2013. Part 2. Ch. 16. pp. 127–143.

119. Cox AD, Barreto L, Ulanova M, et al. Developing a vaccine for Haemophilus influenzae serotype a: Proceedings of a workshop. Can Commun Dis Rep. 2017;43(5):89–95. doi: https://doi.org/10.14745/ccdr.v43i05a02

120. Wiese AD, Griffin MR, Grijalva CG Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Rev Vaccines. 2019;18(4):327–341. doi: https://doi.org/10.1080/14760584.2019.1582337

121. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine‐type invasive pneumococcal disease and X‐ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009;2009(4):CD004977. doi: https://doi.org/10.1002/14651858.CD004977.pub2

122. Sings HL, De Wals P, Gessner BD, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and metaanalysis of observational studies. Clin Infect Dis. 2019;68(12):2135– 2143. doi: https://doi.org/10.1093/cid/ciy920

123. Thompson A, Gurtman A, Patterson S, et al. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine. 2013;31(45):5289–5295. doi: https://doi.org/10.1016/j.vaccine.2013.08.025

124. Ewald H, Briel M, Vuichard D, et al. The clinical effectiveness of pneumococcal conjugate vaccines: a systematic review and meta-analysis of randomized controlled trials. Dtsch Arztebl Int. 2016;113(9):139–146. doi: https://doi.org/10.3238/arztebl.2016.0139

125. Jones LL, Hashim A, McKeever T, et al. Parental and household smoking and the increased risk of bronchitis, bronchiolitis and other lower respiratory infections in infancy: systematic review and meta-analysis. Respir Res. 2011;12(1):5. doi: https://doi.org/10.1186/1465-9921-12-5

126. Watererl G, Bennett L. Improving Outcomes From Communityacquired Pneumonia. Curr Opin Pulm Med. 2015;21(3):219–225. doi: https://doi.org/10.1097/MCP.0000000000000155

127. Gattarello S, Borgatta B, Sole-Violan J, et al. Investigators CIs. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000– 2013). Chest. 2014;146(1):22–31. doi: https://doi.org/10.1378/chest.13-1531

128. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164(6):637– 644. doi: https://doi.org/10.1001/archinte.164.6.637